Patents by Inventor Manfred Reiter
Manfred Reiter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240108431Abstract: A carrier element for supporting at least one medical or dental instrument in a cleaning or care device, wherein the instrument comprises a first transmitting and receiving unit for wireless transmission of electromagnetic radiation having data and/or energy with a second transmitting and receiving unit. A coupling antenna is provided on the carrier element, which receives and in turn emits the electromagnetic radiation wirelessly transmitted between the first and second transmitting and receiving units in order to support the wireless transmission of the electromagnetic radiation between the first transmitting and receiving unit and the second transmitting and receiving unit. A method for wireless transmission of electromagnetic radiation with a corresponding carrier element is also described.Type: ApplicationFiled: December 6, 2023Publication date: April 4, 2024Applicant: W&H Dentalwerk Bürmoos GmbHInventors: Christian Pruckner, Manfred Kainhofer, Michael Reiter
-
Patent number: 11925736Abstract: Dialyzer systems can consolidate multiple technologies and functionalities of blood treatment systems in a significantly integrated fashion. For example, this disclosure describes dialyzer systems that include a magnetically driven and magnetically levitating pump rotor integrated into the dialyzer. Such a dialyzer can be used with treatment modules that include a magnetic field-generating pump drive unit. In some embodiments, the dialyzers include pressure sensor chambers with flexible membranes with which corresponding pressure transducers of the treatment modules can interface to detect arterial and/or venous pressures.Type: GrantFiled: November 12, 2020Date of Patent: March 12, 2024Assignees: Fresenius Medical Care Deutschland GmbH, Fresenius Medical Care Holdings, Inc.Inventors: Massimo Earl Fini, Lynn E. Jensen, Alexander Heide, Dejan Nikolic, Arne Peters, Christoph Wiktor, Marina Wenke, Tommy Huang, Dacey John Ryan, Stefan Kreber, Lothar Leick, Dzhuney Terzi, Hendrik Therre, Manfred Weis, Alain Veneroni, Reinhold Reiter, Michele Marini, Davide Maria Benelli, Brad Yang, Jiunn Teo
-
Patent number: 11780904Abstract: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.Type: GrantFiled: October 30, 2020Date of Patent: October 10, 2023Assignee: Takeda Pharmaceutical Company LimitedInventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt
-
Patent number: 11650159Abstract: The present invention relates to a method of predicting a performance characteristic of a plant or yeast hydrolysate, wherein a plant or yeast hydrolysate sample is measured with 2D fluorescence spectroscopy in powder form. Said method comprises the steps for providing a model based on a predetermined value of a manufacturing parameter of interest. For this purpose a training set consisting of predetermined manufacturing parameter of interest (e.g volumetric productivity parameter, virus titer or cell number) and fluorescence spectroscopic data is used. The fluorescence spectroscopic data is correlated to the values of the manufacturing parameter of interest to obtain a calibration model/model parameters by applying multivariate data analysis. This calibration model is being used to predict the manufacturing parameter of interest for new samples dedicated for the manufacturing process.Type: GrantFiled: November 25, 2019Date of Patent: May 16, 2023Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Renata Baldaszti-Juric, Leopold Grillberger, Wolfgang Langer, Manfred Reiter
-
Patent number: 11421202Abstract: The invention relates to a method for removing a viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. The method comprises subjecting said preparation to filtration for at least about 24 hours through a virus filter having an effective pore size of maximum about 75 nm. Further, the invention relates to the use of a virus filter in filtration of at least about 24 hours, wherein the virus filter has an effective pore size of maximum about 75 nm for the removal of viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. In some embodiments the filtration according to the invention operates at a volumetric capacity of at least about 2000 L/m2.Type: GrantFiled: March 12, 2020Date of Patent: August 23, 2022Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Wolfgang Mundt, Artur Mitterer, Manfred Reiter, Meinhard Hasslacher, Leopold Grillberger, Thomas Kreil
-
Patent number: 11339377Abstract: The present invention refers to a process for purifying virus particles from cell culture, comprising the steps of subjecting the cell culture to centrifugation to get a supernatant fraction of virus particles, incubating said fraction with a nuclease, diluting the fraction with low conductivity buffer, subjecting said diluted fraction to a SO3 chromatography step, performing a washing step with low conductivity buffer, and eluting virus particles.Type: GrantFiled: November 8, 2018Date of Patent: May 24, 2022Assignee: BLUESKY IMMUNOTHERAPIES GMBHInventors: Markus Wolschek, Manfred Reiter, Ales Strancar, Mojca Tajnik Sbaizero
-
Patent number: 11254921Abstract: The present invention provides culture mediums that are useful for the expression of ADAMTS proteins, such as ADAMTS13. Methods for the expression and purification of ADAMTS proteins are also provided. In some embodiments, the mediums and methods of the invention are useful for the expression of ADAMTS proteins having high specific activities. Also provided are ADAMTS, e.g., ADAMTS13, protein compositions with high specific activities, which are expressed and purified according to the methods provided herein.Type: GrantFiled: June 16, 2020Date of Patent: February 22, 2022Assignee: Takeda Pharmaceutical Company LimitedInventors: Leopold Grillberger, Alexandra Spenger, Meinhard Hasslacher, Rana Grillberger, Manfred Reiter
-
Publication number: 20210115110Abstract: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.Type: ApplicationFiled: October 30, 2020Publication date: April 22, 2021Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt
-
Patent number: 10822394Abstract: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.Type: GrantFiled: September 7, 2018Date of Patent: November 3, 2020Assignees: Baxalta GmbH, Baxalta IncorporatedInventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt
-
Publication number: 20200332264Abstract: The present invention refers to a process for purifying virus particles from cell culture, comprising the steps of subjecting the cell culture to centrifugation to get a supernatant fraction of virus particles, incubating said fraction with a nuclease, diluting the fraction with low conductivity buffer, subjecting said diluted fraction to a SO3 chromatography step, performing a washing step with low conductivity buffer, and eluting virus particles.Type: ApplicationFiled: November 8, 2018Publication date: October 22, 2020Inventors: Markus WOLSCHEK, Manfred REITER, Ales STRANCAR, Mojca Tajnik SBAIZERO
-
Publication number: 20200308566Abstract: The present invention provides culture mediums that are useful for the expression of ADAMTS proteins, such as ADAMTS13. Methods for the expression and purification of ADAMTS proteins are also provided. In some embodiments, the mediums and methods of the invention are useful for the expression of ADAMTS proteins having high specific activities. Also provided are ADAMTS, e.g., ADAMTS13, protein compositions with high specific activities, which are expressed and purified according to the methods provided herein.Type: ApplicationFiled: June 16, 2020Publication date: October 1, 2020Inventors: Leopold Grillberger, Alexandra Spenger, Meinhard Hasslacher, Rana Grillberger, Manfred Reiter
-
Publication number: 20200277565Abstract: The invention relates to a method for removing a viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. The method comprises subjecting said preparation to filtration for at least about 24 hours through a virus filter having an effective pore size of maximum about 75 nm. Further, the invention relates to the use of a virus filter in filtration of at least about 24 hours, wherein the virus filter has an effective pore size of maximum about 75 nm for the removal of viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. In some embodiments the filtration according to the invention operates at a volumetric capacity of at least about 2000 L/m2.Type: ApplicationFiled: March 12, 2020Publication date: September 3, 2020Applicants: Baxalta Incorporated, Baxalta GmbHInventors: Wolfgang MUNDT, Artur MITTERER, Manfred REITER, Meinhard HASSLACHER, Leopold GRILLBERGER, Thomas KREIL
-
Patent number: 10745672Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.Type: GrantFiled: January 18, 2019Date of Patent: August 18, 2020Assignees: Baxalta Incorporated, Baxalta GmbHInventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl
-
Patent number: 10724024Abstract: The present invention provides culture mediums that are useful for the expression of ADAMTS proteins, such as ADAMTS13. Methods for the expression and purification of ADAMTS proteins are also provided. In some embodiments, the mediums and methods of the invention are useful for the expression of ADAMTS proteins having high specific activities. Also provided are ADAMTS, e.g., ADAMTS13, protein compositions with high specific activities, which are expressed and purified according to the methods provided herein.Type: GrantFiled: September 8, 2018Date of Patent: July 28, 2020Assignees: Baxalta Incorporated, Baxalta GmbHInventors: Leopold Grillberger, Alexandra Spenger, Meinhard Hasslacher, Rana Grillberger, Manfred Reiter
-
Publication number: 20200225159Abstract: The present invention relates to a method of predicting a performance characteristic of a plant or yeast hydrolysate, wherein a plant or yeast hydrolysate sample is measured with 2D fluorescence spectroscopy in powder form. Said method comprises the steps for providing a model based on a predetermined value of a manufacturing parameter of interest. For this purpose a training set consisting of predetermined manufacturing parameter of interest (e.g volumetric productivity parameter, virus titer or cell number) and fluorescence spectroscopic data is used. The fluorescence spectroscopic data is correlated to the values of the manufacturing parameter of interest to obtain a calibration model/model parameters by applying multivariate data analysis. This calibration model is being used to predict the manufacturing parameter of interest for new samples dedicated for the manufacturing process.Type: ApplicationFiled: November 25, 2019Publication date: July 16, 2020Inventors: Leopold Grillberger, Renata Juric Baldaszti-Juric, Wolfgang Langer, Manfred Reiter
-
Patent number: 10696731Abstract: The present invention relates to oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine and to methods for cultivating cells in said oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine. The invention also relates to methods for expressing at least one protein in a medium comprising at least 0.5 mg/L of a polyamine and to methods for producing at least one virus in a medium comprising at least 0.5 mg/L of a polyamine.Type: GrantFiled: August 7, 2017Date of Patent: June 30, 2020Assignees: Baxalta GmbH, Baxalta IncorporatedInventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt, Artur Mitterer
-
Patent number: 10655099Abstract: The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes.Type: GrantFiled: October 29, 2018Date of Patent: May 19, 2020Assignees: Baxalta Incorporated, Baxalta GmbHInventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
-
Patent number: 10527551Abstract: The present invention relates to a method of predicting a performance characteristic of a plant or yeast hydrolysate, wherein a plant or yeast hydrolysate sample is measured with 2D fluorescence spectroscopy in powder form. Said method comprises the steps for providing a model based on a predetermined value of a manufacturing parameter of interest. For this purpose a training set consisting of predetermined manufacturing parameter of interest (e.g volumetric productivity parameter, virus titer or cell number) and fluorescence spectroscopic data is used. The fluorescence spectroscopic data is correlated to the values of the manufacturing parameter of interest to obtain a calibration model/model parameters by applying multivariate data analysis. This calibration model is being used to predict the manufacturing parameter of interest for new samples dedicated for the manufacturing process.Type: GrantFiled: December 18, 2014Date of Patent: January 7, 2020Assignees: Baxalta Incorporated, Baxalta GmbHInventors: Leopold Grillberger, Renata Baldaszti-Juric, Wolfgang Langer, Manfred Reiter
-
Publication number: 20190352615Abstract: The present invention provides a method for purifying virus particles from host cells infected with virus, wherein the virus particles are treated with benzonase and polyethylene glycol and the use of said purified viruses for therapeutic compositions.Type: ApplicationFiled: December 21, 2017Publication date: November 21, 2019Inventors: Markus WOLSCHEK, Manfred REITER
-
Publication number: 20190153400Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.Type: ApplicationFiled: January 18, 2019Publication date: May 23, 2019Inventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl